<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688531</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40183E</org_study_id>
    <nct_id>NCT01688531</nct_id>
    <nct_alias>NCT01718665</nct_alias>
  </id_info>
  <brief_title>A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients</brief_title>
  <official_title>A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: IRB Services, Ontario</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>USA:IRB, East Baltimore Campus, Baltimore</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Comité de Protection des Personnes Ouest VI</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, international, multi-centre, randomized, investigator blinded study in acne
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Description and documentation of acne lesions</measure>
    <time_frame>over 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment effect on acne lesions</measure>
    <time_frame>over 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>CD0271/CD1579, vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD0271/CD1579, vehicle</intervention_name>
    <arm_group_label>CD0271/CD1579, vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 to 35 years inclusive

          -  Subjects with active, moderate acne

        Exclusion Criteria:

          -  The subject has a secondary acne form (chloracne, drug-induced acne, etc.)
             (Screening)

          -  The subject has a severity of acne that is not amenable to treatment with
             CD0271-CD1579 (Screening)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 16, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
